Incyte Corporation’s (INCY) Buy Rating Reaffirmed at Jefferies Group LLC

Incyte Corporation (NASDAQ:INCY)‘s stock had its “buy” rating reissued by research analysts at Jefferies Group LLC in a research note issued to investors on Tuesday. They presently have a $148.00 target price on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective indicates a potential upside of 21.03% from the company’s previous close.

Several other brokerages also recently weighed in on INCY. Zacks Investment Research downgraded Incyte Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, April 5th. Piper Jaffray Companies reaffirmed a “neutral” rating and set a $124.00 target price on shares of Incyte Corporation in a research note on Monday, April 17th. Raymond James Financial, Inc. reaffirmed a “hold” rating on shares of Incyte Corporation in a research note on Monday, April 17th. William Blair assumed coverage on Incyte Corporation in a research note on Tuesday, March 21st. They set an “outperform” rating on the stock. Finally, Barclays PLC set a $135.00 target price on Incyte Corporation and gave the company a “buy” rating in a research note on Saturday, April 8th. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $141.93.

Analyst Recommendations for Incyte Corporation (NASDAQ:INCY)

Shares of Incyte Corporation (INCY) traded up 2.834% during midday trading on Tuesday, reaching $125.745. The company’s stock had a trading volume of 1,122,397 shares. The firm’s market capitalization is $25.75 billion. The company’s 50-day moving average price is $124.10 and its 200 day moving average price is $123.32. Incyte Corporation has a 1-year low of $71.75 and a 1-year high of $153.15.

Incyte Corporation (NASDAQ:INCY) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.01. The firm had revenue of $384.08 million for the quarter, compared to the consensus estimate of $359.19 million. Incyte Corporation had a negative return on equity of 20.09% and a negative net margin of 8.72%. The firm’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.12 EPS. On average, equities research analysts forecast that Incyte Corporation will post ($0.75) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Stock Observer and is owned by of Stock Observer. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.thestockobserver.com/2017/06/20/incyte-corporations-incy-buy-rating-reaffirmed-at-jefferies-group-llc.html.

In related news, Director Jean Jacques Bienaime bought 500 shares of the firm’s stock in a transaction that occurred on Monday, May 15th. The shares were acquired at an average cost of $115.00 per share, for a total transaction of $57,500.00. Following the acquisition, the director now directly owns 4,177 shares of the company’s stock, valued at approximately $480,355. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Steven H. Stein sold 32,000 shares of Incyte Corporation stock in a transaction on Friday, April 7th. The stock was sold at an average price of $137.88, for a total value of $4,412,160.00. Following the completion of the transaction, the executive vice president now owns 41,648 shares in the company, valued at $5,742,426.24. The disclosure for this sale can be found here. Over the last 90 days, insiders purchased 3,500 shares of company stock worth $464,670 and sold 109,544 shares worth $14,547,094. Insiders own 13.70% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp increased its position in shares of Incyte Corporation by 110.7% in the first quarter. State Street Corp now owns 7,581,684 shares of the biopharmaceutical company’s stock worth $1,013,437,000 after buying an additional 3,983,207 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Incyte Corporation by 22.7% in the first quarter. Vanguard Group Inc. now owns 15,415,857 shares of the biopharmaceutical company’s stock worth $2,060,638,000 after buying an additional 2,847,907 shares in the last quarter. Norges Bank acquired a new position in shares of Incyte Corporation during the fourth quarter worth $180,561,000. Victory Capital Management Inc. acquired a new position in shares of Incyte Corporation during the first quarter worth $85,751,000. Finally, Geode Capital Management LLC increased its position in shares of Incyte Corporation by 42.0% in the first quarter. Geode Capital Management LLC now owns 1,780,064 shares of the biopharmaceutical company’s stock worth $237,618,000 after buying an additional 526,163 shares in the last quarter. Institutional investors and hedge funds own 92.79% of the company’s stock.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply